Form 4: Apellis Pharmaceuticals Executive Exercises Stock Options
SEC Form 4 Filing
Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, exercised stock options and acquired common stock on August 12, 2024.
Summary
- On August 12, 2024, Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, exercised stock options.
- He acquired 5,201 shares of common stock at a price of $13.85 per share.
- Following the transaction, DeLong directly owns 60,395 shares of common stock.
- The exercised stock options were granted on February 8, 2019, and were fully vested.
- DeLong now holds 14,799 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't convey any explicit positive or negative sentiment about the company's performance or prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency into the trading activities of company executives. It is standard practice for officers to exercise stock options as part of their compensation.
Key Dates
| Date | Description |
|---|---|
| February 8, 2019 | Date the stock options were granted. |
| April 30, 2024 | Date of ESPP purchase. |
| August 12, 2024 | Date of the stock option exercise and common stock acquisition. |
| August 13, 2024 | Date of signature on the Form 4 filing. |
| February 27, 2029 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.